Background and Objectives: Women with unilateral early-stage breast cancer are
| INTRODUCTION
Over the past two decades, an increasing number of women in the United States have been choosing to undergo contralateral prophylactic mastectomy (CPM) for in situ and early-stage invasive breast cancer (T1-3), despite a decline in contralateral breast cancer (CBC) incidence secondary to the use of adjuvant systemic therapy. [1] [2] [3] [4] The American Joint Committee on Cancer (AJCC) defines locally advanced (T4) breast cancer as a tumor of any size with direct extension to the chest wall (beyond or other than the pectoralis major) and or to the skin (with ulceration or nodules), or inflammatory (T4d) breast carcinoma. 5 While chest wall invasion (T4a), skin nodule or ulceration (T4b), and both chest wall invasion and skin nodule or ulceration extension (T4c) breast cancer subtypes vary by extent of local invasion, the inflammatory (T4d) breast cancer subtype, is a rare, aggressive form of rapid-onset (shorter than 6 months) carcinoma that presents with erythema and or edema characterized by "peau d'orange" of the skin involving at least onethird of the breast. 6 Classification of inflammatory breast cancer is clinically significant as it has a worse prognosis compared with all other T4 classifications. 7, 8 Surgical management of locally advanced clinical T4abc tumors depends on the extent of disease and response to neoadjuvant chemotherapy therapy, with standard therapy consisting of upfront systemic therapy followed by mastectomy and radiation, while patients who are exceptional responders might be considered for breast conservation. 9, 10 The standard of care for inflammatory breast cancer (T4d) remains modified radical mastectomy and postmastectomy radiation therapy following neoadjuvant chemotherapy according to national and international expert panel recommendations 6 as well as National Comprehensive Cancer Network (NCCN) guidelines. 7, 11 There are no current guidelines or recommendations regarding the use of CPM for women with locally advanced breast cancer. As noted in the NCCN guidelines, immediate breast reconstruction (IBR) is contraindicated in the setting of inflammatory breast cancer secondary to the high risk of recurrence rate, need to resect a large skin paddle of skin, and desire to proceed expeditiously to postmastectomy radiation therapy. 
| RESULTS
A total of 23 943 women met study inclusion criteria. Of all the women studied, 41% had a clinical diagnosis of T4abc (n = 9824), 35%
had a clinical diagnosis of T4d (n = 8321), and 24% had a clinical diagnosis of T4 NOS (n = 5798). Twenty-two percent of the cohort had lymphovascular invasion, and 70% had positive regional lymph nodes. Fifty-eight percent of the cohort received neoadjuvant therapy, 17% received adjuvant systemic chemotherapy, and 65%
received postmastectomy radiotherapy (Table 1) .
| Trends of CPM
Cumulative CPM rates for the entire period of 2004 to 2014 are illustrated in Figure 1 . The overall CPM rate among women with T4 breast cancer was 18%. Results of the stratified analysis showed that the CPM rate in the clinical T4d group was higher than that in the T4abc group (23% vs 15%; P < 0.05) ( Figure 1 ).
Temporal CPM trends for the period of study are charted in 
| CPM versus unilateral mastectomy: univariate analyses
Univariate analyses of factors associated with CPM are presented in Table 1 ; women of younger age, white race, and higher education were more likely to have chosen CPM. Women with payers consisting of private insurance, managed care, or other government insurance were more likely to undergo CPM (P < 0.001). Contrastingly, non-white women with a higher comorbidity index and Medicare as the primary payer were less likely to have undergone CPM (P < 0.05). An analysis of oncologic factors revealed that women with smaller clinical tumor size and positive lymph nodes were also more likely to have undergone CPM. Women in the CPM group were also more likely to have negative surgical margins and to have received neoadjuvant or adjuvant systemic chemotherapy as well as postmastectomy radiotherapy (all P < 0.05) ( Table 1) . In an attempt to account for tumor downstaging by neoadjuvant chemotherapy, we assessed CPM rates among women with a clinical T4abc disease who had AJCC pathologic tumor stage pT4 versus pT0-3 tumors following neoadjuvant chemotherapy (n = 5111). Those women who had a decrease in pathologic tumor stage (pT ≤ 3) following neoadjuvant chemotherapy were significantly more likely to undergo CPM (64 vs 53%; P < 0.001). When analyzing the type of cancer care facility, community cancer programs were less likely to perform CPM compared with other cancer programs (P < 0.001) ( Table 1 ). Table 2 ).
| Independent predictors of CPM
Receipt of adjuvant or neoadjuvant chemotherapy, as well as postmastectomy radiotherapy, was also associated with an increase in CPM rate (All P < 0.05) ( 
| Contralateral prophylactic mastectomy and immediate breast reconstruction
Among all women who underwent CPM, the cumulative IBR rate was 22% for the study period (n = 948/4302) ( Table 3 ). An upward trend in the IBR rate from 14% to 27% was observed across the study period, at an annual growth rate of 16% (P < 0.001) ( Table 3 ). The overall IBR rate in women who underwent CPM for T4abc and T4d was 26% and 18%, respectively (Table 1) . Trend analyses of the women with IBR showed increasing annual rates of CPM of 18% and 13% for T4abc and T4d, respectively (both P < 0.001; data not shown). 16 When comparing women with T4d breast cancer to those with T4abc subtypes, CPM was more common in the T4d group for the overall study period (23% vs 15%; P < 0.05).
| DISCUSSION
The Mayo Clinic has reported an institutional rate of CPM as high as 36% and 45% among women with T4 and T4d breast cancer, respectively, for the period 2008 to 2015, 20 although it did not analyze temporal trends.
The increasing CPM rates observed among women with T4d tumors is of particular interest, as inflammatory breast cancer has historically been associated with a more aggressive disease course, higher local recurrence, and mortality rates, compared with earlierstage disease. [8] [9] [10] 21, 22 In our study, the overall cross-sectional rate of CPM was 23% in the T4d group, which showed an 8% annual growth patients. 13, 18, 28 In a study exploring predictors of CPM among women with in situ and early-stage invasive breast cancer, young age, and availability of IBR explained the highest variation, with coefficients of determination of 32% and 29%, respectively.
18
Although speculative, one potential factor affecting the rising trend of IBR in women with clinically T4 non-metastatic breast cancer may be the Women's Health and Cancer Right Act of 1998, which requires all women undergoing surgery for any stage of breast cancer be offered reconstruction for the native breast removed as well as the contralateral breast; studies have reported this association for women with early-stage breast cancer undergoing IBR. 15 Our multivariable model also demonstrated that women with the T4 disease who received neoadjuvant therapy were over three times more likely to have chosen CPM than unilateral mastectomy (AOR:
3.79; P < 0.001) ( Table 2) . Surprisingly, a subcohort of women with Future studies, exploring the drivers of CPM using innovative research methodologies, may help illustrate the reasons behind the decision to perform CPM. One such investigation is being used at our institution using a market-research tool-conjoint analysis, which emulates real-life scenarios confronting patients while they are making the critical decision for unilateral breast cancer.
Furthermore, there are ongoing efforts, such as published consensus statements from the American Society of Breast 
